7th Dec 2018 11:26
LONDON (Alliance News) - ImmuPharma PLC on Friday said it is currently in the process of making Lupuzor, its drug for the treatment of lupus, available to patients via its managed access programme.
The drug discovery & development company said the programme is progressing to plan, including the work regarding regulatory processes.
Furthermore, an open label study for Lupuzor is also progressing as planned after the recruitment of 62 patients in the US and Europe. The company expects to report results from the study in the second quarter of 2019.
With regards to its Nucant cancer programme, Immupharma said that its collaboration with Incanthera Ltd is progressing well with the companies "making good progress".
For its French subsidiary, Ureka, which the company is looking to divest, Immupharma said it has decided to engage a R&D specialist advisory firm, to evaluate Ureka's technologies and drug candidates ahead of the transaction.
Meanwhile, from a regulatory perspective, ImmuPharma is in the process of engaging a replacement nominated adviser, after Northland Capital Partners agreed to relinquish its status from February.
Shares in the company were trading flat at 12.25 pence each on Friday.
Related Shares:
Immupharma